Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Лёгочная гипертензия у новорожденных

Список литературы

  1. Simonneau G., Gatzoulis M., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34–D41.
  2. van Loon R., Roofthooft M., Hillege H. et al. Pediatric pulmonary hypertension in the Netherlands: Epidemiology and characterization during the period 1991 to 2005. Circulation.2011;124(16):1755-1764.
  3. Peacock A., Murphy N., McMurray J. et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104-109.
  4. Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.Galie´ N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227–237.
  5. Sitbon O., Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012; 21: 126, 321–327.
  6. Klinger J.. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007;28(1):143–167/
  7. Ji R., Meng J., et al. Functional changes in pulmonary arterial endothelial cells associated with BMPR2 mutations. PLoS One. 2014;9(9):e106703
  8. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest.2008;118(7):2372-2379.
  9. Humbert M. Morrell N., Archer S. et al. Cellular and molecular pathobiology of pulmonary arterialhypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):13S-24S.
  10. Runo J., Vnencak-Jones C., Prince M et al..Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med.2003;167:889–894.
  11. Sztrymf B., Coulet F., Girerd B. et al. Clinical outcomesof pulmonary arterial hypertension in carriers of BMPR2 mutation.Am J Respir Crit Care Med. 2008;177:1377–1383
  12. Roberts K., McElroy J., Wong W. et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 2004;24:371–374
  13. Soubrier F., Chung W., Machado R. et al. Genetics and Genomics of Pulmonary Arterial Hypertension. Am Coll Cardiol 2013;62:D13–21.
  14. Moledina S., Hislop A., Foster H. et al. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart 2010;96:1401-6.
  15. Peacock A., Murphy N.., McMurrey,J. et al. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal 2007;30:104–109.
  16. Alghamdi M., Steinraths M., Panagiotopoulos C. et al. Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome in a pediatric patient. Pediatr Cardiol. 2010;31:872–874.
  17. Lo S., Liu J., Chen F. et al. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inherit Metab Dis. 2011;34:643–650.
  18. Stewart D., Cogan J. Kramer M. et al. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest. 2007;132:798–808.
  19. Hilgendorff A, Apitz C, Bonnet D, Hansmann G. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. // Heart. 2016 May;102 Suppl 2:ii49-56.
  20. Lammers A.E., Apitz C., Zartner P. et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/ paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. Heart 2016;102:ii1–13.
  21. Hansmann G., Apitz C., Abdul-Khaliq H. et al. Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102:ii86–ii100.
  22. Abman S., Hansmann G., Archer S.. et al. Pediatric Pulmonary Hypertension. Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015;132:2037-2099
  23. Galie N., Humbert M., Vachiery J. et al. 2015 ESC/ERS Guidelines for the diagnosisand treatment of pulmonary hypertension. European Heart Journal 2016; 37:67–119
  24. Ivy D.D., Abman S.H., Barst RJ, et al. Paediatric pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D117–26.
  25. Горбачевский С.В., Шмальц А.А., Гренадеров М.А.,Белкина М.В.,Рахмонов К.Х., Айбазов Р.А. и др. Хирургическое лечение пограничных состояний у больных с заболеваниями сердечнососудистой системы, осложненных легочной гипертензией. Бюллетень НЦССХ им. А.Н. Бакулева РАМН Сердечно-сосудистые заболевания. 2017; 18 (1): 73-80
  26. Шмальц А.А., Белкина М.В., Горбачевский С.В. Специфические легочные вазодилататоры после операции Фонтена. Детские болезни сердца и сосудов. 2017; 14 (1): 16-25
  27. Шмальц А.А., Нишонов Н.А. Атриосептостомия у больных с легочной гипертензией. Грудная и сердечно-сосудистая хирургия. 2015. № 5. С. 18-25. 29. Горбачевский С.В., Шмальц А.А., Белкина М.В., Гренадеров М.А., Барышникова И.Ю., Пурсанов М.Г., Татарян Ф.Э., Горчакова А.И. Анастомоз Поттса у детей с легочной гипертензией: 7 операций в одной клинике и обзор мирового опыта. Детские болезни сердца и сосудов. 2016. Т. 13. №4. С. 189-198. 30. Горбачевский С.В., Белкина М.В., Шмальц А.А. Айбазов Р.А. Применение Бозентана у больных с осложненным течением гемодинамической коррекции функционально единственного желудочка и исходной легочной гипертензией. Бюллетень НЦССХ им. А.Н. Бакулева РАМН Сердечно-сосудистые заболевания. 2015; 16 (S3): 14
  28. Горбачевский С.В., Мажидов У.А., Горчакова А.И. Хирургическое лечение врожденных пороков сердца с синдромом Эйзенменгера. Грудная и сердечно-сосудистая хирургия. 2016. Т. 58. № 3. С. 124-129
  29. Горбачевский С.В., Шмальц А.А., Белкина М.В., Гренадеров М.А., Рахмонов К.Х. Алгоритм определения показаний к хирургическому лечению врожденных пороков сердца с гипертензионной сосудистой болезнью легких. Бюллетень НЦССХ им. А.Н. Бакулева РАМН Сердечно-сосудистые заболевания. 2015; 16( S3): 12.
  30. Горбачевский С.В., Шмальц А.А., Белкина М.В. Гренадеров М.А., Барышникова И.Ю., Пурсанов М.Г. и др. Алгоритм диагностики гипертензионной сосудистой болезни легких, ассоциированной с врожденными пороками сердца. Бюллетень НЦССХ им. А.Н. Бакулева РАМН Сердечно-сосудистые заболевания. 2015; 16( S3): 12.
  31. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. и др. Педиатрическая гипертензионная сосудистая болезнь легких, ассоциированная с врожденными пороками сердца. Клинические рекомендации. М.:НЦССХ им. А.Н.Бакулева. 2015.
  32. Горбачевский С.В., Шмальц А.А. Гипертензионная сосудистая болезнь легких, ассоциированная с врожденными пороками сердца. В кн.: Детская кардиохирургия. Руководство для врачей. М., 2016: 833-850.
  33. Бокерия Л.А., Горбачевский С.В., Школьникова М.А.. Легочная гипертензия у детей.-Москва, 2013-416 с.
  34. Cerro M., Abman S., Diaz G. et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1:286–298.
  35. Lammers A., Adatia I., Cerro M.J. et al. Functional classification of pulmonary hypertension in children: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1:280–285.
  36. Van Loon R., Roofthooft M., van Osch-Gevers M et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr.2009;155:176–182.
  37. Barst R., Ertel S., Beghetti M., Ivy D. Pulmonary arterial hypertension: A comparison between children and adults. Eur Respir J. 2011;37(3):665-677.
  38. Berger R., Beghetti M., Humpl T et al. Clinical features of paediatric pulmonary hypertension: A registry study. Lancet. 2012;379(9815):537-546.
  39. Fraisse A., Jais X., Schleich J. et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis. 2010;103(2):66-74.
  40. Van Albada M., Loot F., Fokkema R. et al.. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res. 2008;63(3):321-327.
  41. Fijalkowska A., Kurzyna M., Torbicki A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129:1313–1321. doi: 10.1378/chest.129.5.1313.
  42. Lowenthal A., Camacho B., Lowenthal S. et al. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease. Am J Cardiol. 2012;109:866–872.
  43. Tobias J. B-type natriuretic peptide: diagnostic and therapeutic applications in infants and children. J Intensive Care Med. 2011;26:183–195.
  44. Bernus A., Wagner B., Accurso F. et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest. 2009;135(3):745-751.
  45. Lammers A., Hislop A., Haworth S. et al.. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol. 2009;135(1):21-26.
  46. Takatsuki S., Wagner B., Ivy D. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis.2012;7(3):259-267.
  47. Smadja D., Gaussem P., Mauge L. et al. Circulating endothelial cells: A new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation.2009;119(3):374-381
  48. Hoeper M., Pletz M., Golpon H., Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007; 29:944–950.
  49. .Bonderman D., Wexberg P., Martischnig A. et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J 2011;37:1096–1103.
  50. Rich J., Thenappan T., Freed B. et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013;167:669–676.
  51. Sun P., Jiang X., Gomberg-Maitland M. et al. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest 2012;141:374–380..
  52. Babyn P., Gahunia H., Massicotte P. Pulmonary thromboembolism in children. Pediatr Radiol 2005;35:258-74.
  53. Sun X., Hansen J., Oudiz R. et al. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003;41:1028–103.
  54. Hinderliter A., Willis P. 4th, Long W. et al. PPH Study Group. Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension. Am J Cardiol.2003;91:1033–1037, A9.
  55. Ploegstra M., Roofthooft M., Douwes J. et al. Echocardiography in Pediatric Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging. 2015;8:e000878
  56. Fisher M., Forfia P., Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:615–621.
  57. Ommen S. Nishimura R. Hurrell D. et al. Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin Proc. 2000;75:24–29.
  58. Peterson A., Deatsman S., Frommelt M. et al.. Correlation of echocardiographic markers and therapy in persistent pulmonary hypertension of the newborn. Pediatr Cardiol. 2009;30:160–165.
  59. Koestenberger M., Ravekes W., Everett A. Right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values. J Am Soc Echocardiogr. 2009;22:715–719.
  60. Morcos P., Vick G. 3rd, Sahn D., Jerosch-Herold M.. et al. Correlation of right ventricular ejection fraction and tricuspid annular plane systolic excursion in tetralogy of Fallot by magnetic resonance imaging. Int J Cardiovasc Imaging. 2009;25:263–270
  61. Lammers A., Diller G., Odendaal D. et al. Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension. Arch Dis Child 2011; 96: 141–147
  62. Taylor C., Derrick G. McEwan A. et al. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension.Br J Anaesth. 2007;98:657–661.
  63. Carmosino M., Friesen R., Doran A., Ivy D. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg. 2007;104:521–527.
  64. Apitz C., Hansmann G., Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102:ii23–9.
  65. Latus H., Kuehne T., Beerbaum P. et al. Cardiac magnetic resonance and computed tomography imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102:ii30–35.
  66. Berger R., Bonnet D. Treatment options for paediatric pulmonary arterial hypertension. EurRespir Rev. 2010;19(118):321-330.
  67. Kleinman ME, de Caen AR, Chameides L, Atkins DL et al. Pediatric Basic and Advanced Life Support Chapter Collaborators. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with treatment recommendations. Pediatrics. 2010;126:e1261–e1318
  68. Maslach-Hubbard A., Bratton S. Extracorporeal membrane oxygenation for pediatric respiratory failure: History, development and current status. World J Crit Care Med 2013; 2(4): 29-39.
  69. Sitbon O., Humbert M., Jais X. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105-3111.
  70. Barst R., Maislin G., Fishman A.. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99(9):1197-1208.
  71. Douwes J., van Loon RL, Hoendermis ES, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: Occurrence and prognostic value when comparing three response criteria. Eur Heart J. 2011;32(24):3137-3146.
  72. Kahveci H., Yilmaz O., Avsar U. et al.. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J.2004;24(6):1007-1010.
  73. D’Alto M., Romeo E., Argiento P. et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and eisenmenger physiology. Int J Cardiol.2012;155(3):378-382. Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest. 2006;36 Suppl 3:32-38.
  74. Porhownik N., Al-Sharif H., Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J. 2008;15(8):427-430.
  75. Mathai S., Girgis R., Fisher M. et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29(3):469-475.
  76. Douwes J., Roofthooft M., Van Loon RL et al. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. Heart. 2014;100(3):224-230.
  77. Hislop A., Moledina S., Foster H et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J. 2011;38(1):70-77.
  78. Barst R., Ivy D., Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73(4):372-382.
  79. Beghetti M., Haworth S., Bonnet D. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: The FUTURE-1 study. Br J Clin Pharmacol. 2009;68(6):948-955.
  80. Beghetti M., Hoeper M., Kiely D. et al. Safety experience with bosentan in 146 children 2-11years old with pulmonary arterial hypertension: Results from the european postmarketing surveillance program. Pediatr Res. 2008;64(2):200-204.
  81. Rosenzweig E., Ivy D., Widlitz A. et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697-704.
  82. Ivy D., Rosenzweig E., Lemarie J. et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010;106(9):1332-1338.
  83. Souza R.o, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  84. Klinger J., Oudiz R., Spence R. et al. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol. 2011;108(2):302-307.
  85. Takatsuki S., Rosenzweig E., Zuckerman W. et al. Clinical safety, pharmacokinetics,and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol.2013;48(1):27-34.
  86. Barst R., Ivy D., Gaitan G. et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.Circulation. 2012;125(2):324-334.
  87. Krishnan U. Krishnan S. Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008;29:1082-6.
  88. Mourani P., Sontag M., Ivy D., Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84.
  89. Michelakis E., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108(17):2066–2069
  90. Barst R.., Beghetti M., Pulido T., Layton G. STARTS-2. Long-Term Survival With Oral Sildenafil Monotherapy in Treatment-Naive Pediatric Pulmonary Arterial Hypertension. Circulation. 2014;129:1914-1923.
  91. Xia Y., Yan W., Chen H. Efficacy and safety of sildenafi l in the treatmentof high altitude heart disease associated with severe pulmonary arterial hypertension in children: a preliminary evaluation. Zhongguo Dang Dai Er Ke Za Zhi. 2014;16(7):745–748
  92. El Midany A, Mostafa E., Azab S., Hassan GA. Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure. Interact Cardiovasc Thorac Surg. 2013;17(6):963–968
  93. Vargas-Origel A, Gomez-Rodriguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcon-Santos SB, AmadoR–Licona N. The use of sildenafi l in persistent pulmonary hypertension of the newborn. Am J Perinatol.2010;27(3):225–230.
  94. Baquero H., Soliz A., Neira F., Venegas M., Sola A. Oral sildenafi l in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006;117(4):1077–1083.
  95. Ivy D., Doran A., Smith K. et al. Short- and longterm effects of inhaled iloprost therapy in children with pulmonary arterialhypertension. J Am Coll Cardiol. 2008;51:161–16
  96. Micheletti A., Hislop A., Lammers A. et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart. 2006;92(7):969-972.
  97. Law M., Grifka R., Mullins C., Nihill M. Atrial septostomy improves survival in select patients with pulmonary hypertension. Am Heart J. 2007;153(5):779-784.
  98. Sandoval J. Gaspar J., Pulido T. et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998;32(2):297-304.
  99. Blanc J., Vouhe P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med.2004;350(6):623.
  100. Gorbachevskiy S.., Shmalts A., Zaets S. Potts Shunt in Patients with Suprasystemic Pulmonary Arterial Hypertension: Does the Size Matter? Anatomy & Physiology 2017;7(2): e140.
  101. González-Saiz L., Fiuza-Luces C., Sanchis-Gomar F. et al. Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial. Int J Cardiol. 2017;231:277-283.
  102. Morris N., Kermeen F., Holland A. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev. 2017;19;1:CD011285.
  103. Bussotti M., Gremigni P., Pedretti R. et al. Effects of an outpatient service rehabilitation programme in patients affected by pulmonary arterial hypertension: an observational study. Cardiovasc Hematol Disord Drug Targets. 2016 Nov 30.
  104. Roselien B., Andrea A., Véronique A. Cornelissen Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015; 15: 40.
  105. Zijlstra W., Douwes J., Rosenzweig E., et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol. 2014;63(20):2159–2169
  106. D’Alonzo G., Barst R., Ayres S. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–9.
  107. Haworth S., Hislop A. Treatment and survival in children with pulmonary arterial hypertension: The UK pulmonary hypertension service for children 2001-2006. Heart. 2009;95(4):312-317.
  108. Barst R., McGoon M., Elliott C., Foreman A. et al. Survival in childhood pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012;125(1):113-122.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*